It is only adjuvant nivolumab in muscle-invasive UC with tumor cell PD-L1 expression >1% and a high risk of recurrence following the surgery considered a standard of care based on the Checkmate-274 trial, including patients with UTUC. The gene discussed is CD274; the disease is renal pelvis/ureter urothelial carcinoma.